Skip to main content
SpringerLink
Log in

Hormone Replacement Therapy in Postmenopausal Women With Diabetes Mellitus

A Risk-Benefit Assessment

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Hormone replacement therapy (HRT) has been shown to be beneficial in reducing osteoporosis and alleviating climacteric symptoms. HRT has been suggested to reduce the risk for coronary heart disease (CHD), but data are controversial. Unopposed estradiol therapy seems to have a favourable effect on lipid profile and glucose tolerance whereas addition of a progestogen may attenuate these favourable metabolic changes.

Data on HRT in women with diabetes mellitus are scarce but of potential interest since these women are often characterised by hyperandrogenicity, insulin resistance and dyslipidaemia and are at a high risk for developing CHD. Present evidence suggests that short term unopposed oral estradiol therapy has a beneficial effect on glucose homeostasis, lipid profile and fibrinolytic activity, which may be compatible with a reduced risk for CHD. Accordingly, it may be hypothesised that HRT in women with diabetes mellitus may be at least as beneficial as in women without diabetes mellitus. However, women with diabetes mellitus are at increased underlying risk for venous thromboembolism and endometrial cancer. Whether HRT further increases this risk is not yet clear, but this possibility must be considered.

It is, however, likely that the benefits with HRT in postmenopausal women with diabetes mellitus outweigh the risks, but randomised studies are required before any more definite risk-benefit assessment can be made long term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Sturdee DW. Hormone replacement therapy: the benefits and risks. Prescr J 1994; 34: 234–42

    Google Scholar 

  2. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992 Oct; 99: 821–8

    Article  PubMed  CAS  Google Scholar 

  3. Grodstein FG, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75

    Article  PubMed  CAS  Google Scholar 

  4. Grodstein FG, Stampfer MJ, Manson JAE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–61

    Article  PubMed  CAS  Google Scholar 

  5. Sourander L, Rajala T, Räihä I, et al. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998; 352: 1965–9

    Article  PubMed  CAS  Google Scholar 

  6. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13

    Article  PubMed  CAS  Google Scholar 

  7. Barrett-Connor E, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991; 265: 627–31

    Article  PubMed  CAS  Google Scholar 

  8. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165–75

    Google Scholar 

  9. Lindstedt G, Lundberg P-A, Lapidus L, et al. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. Diabetes 1991; 123–8

    Google Scholar 

  10. Haffner SM, Valdez RA, Morales PA, et al. Decreased sex-hormone-binding globulin predicts non-insulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 1993; 77: 56–60

    Article  PubMed  CAS  Google Scholar 

  11. Lapidus L, Lindstedt G, Lundberg P-A, et al. Concentrations of sex-hormone-binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem 1986; 32: 146–52

    PubMed  CAS  Google Scholar 

  12. Goddard M. The cost effectiveness of hormone replacement therapy: a review. Discussion paper 73. York: Centre for Health Economics, University of York, 1990

    Google Scholar 

  13. Matthews K, Meilahn E, Kuller L, et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641–6

    Article  PubMed  CAS  Google Scholar 

  14. Walton C, Godsland I, Proudler A, et al. The effects of menopause on insulin sensitivity, secretion and elimination in nonobese, healthy women. Eur J Clin Invest 1993; 23: 466–73

    Article  PubMed  CAS  Google Scholar 

  15. Godsland IF, Walton C, Stevenson JC. Impact of menopause on metabolism. In: Diamond MP, Naftolin F, editors. Metabolism in the female life cycle. Rome: Ares Serono Symposia, 1993: 171–89

    Google Scholar 

  16. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069–75

    Article  PubMed  CAS  Google Scholar 

  17. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990; 10: 531–4

    Article  PubMed  CAS  Google Scholar 

  18. Manson JA, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin dependent diabetes mellitus. Ann Epidemiol 1992; 2: 665–73

    Article  PubMed  CAS  Google Scholar 

  19. Silfverstolpe G, Gustafson A, Samsioe G, et al. Lipid metabolic studies in oophorectomised women: effects induced by two different estrogens on serum lipids and lipoproteins. Gynecol Obstet Invest 1980; 11: 161–9

    Article  PubMed  CAS  Google Scholar 

  20. Larsson-Cohn U, Wallentin L. Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. Acta Endocrinol 1977; 86: 583–96

    PubMed  CAS  Google Scholar 

  21. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208

    Article  Google Scholar 

  22. Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987–95

    PubMed  CAS  Google Scholar 

  23. Thom M, Chakravarti S, Oram D, et al. Effect of hormone replacement therapy on glucose tolerance in postmenopausal women. Br J Obstet Gynecol 1977; 84: 776–84

    Article  CAS  Google Scholar 

  24. Ajabor LN, Tsai CC, Vela P, et al. Effects of exogenous estrogen on carbohydrate metabolism in postmenopausal women. Am J Obstet Gynecol 1972; 113: 383–7

    PubMed  CAS  Google Scholar 

  25. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846–53

    Article  PubMed  CAS  Google Scholar 

  26. Luotola H, Pyörälä T, Loikkanen M. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas 1986; 8: 245–53

    Article  PubMed  CAS  Google Scholar 

  27. Crook D, Godsland IF, Hull J, et al. Hormone replacement therapy with dydrogesterone and 17 β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24-month follow-up. Br J Obstet Gynaecol 1997; 104(3): 298–304

    Article  PubMed  CAS  Google Scholar 

  28. Matute M, Kalkhoff RK. Sex steroid influence on hepatic gluconeogenesis and glycogen formation. Endocrinology 1973; 92: 762–8

    Article  PubMed  CAS  Google Scholar 

  29. Burke C. Biologically active cortisol in plasma of oestrogen-treated and normal subjects. BMJ 1969; 2: 798–800

    Article  PubMed  CAS  Google Scholar 

  30. Rincon J, Holmäng A, Wahlström EÖ, et al. Mechanisms behind insulin resistance in rat skeletal muscle following oophorectomy and additional testosterone treatment. Diabetes 1996; 45: 615–21

    Article  PubMed  CAS  Google Scholar 

  31. Andersson B, Mattsson L-Å, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 638–43

    Article  PubMed  CAS  Google Scholar 

  32. Brussaard HE, Leuven JA, Frölich M, et al. Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997; 40: 843–9

    Article  PubMed  CAS  Google Scholar 

  33. Andersson B, Mattsson L-Å. The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM. Acta Obstet Gynecol Scand 1999; 78: 260–1

    Article  PubMed  CAS  Google Scholar 

  34. Mosnier-Pudar H, Faguer B, Guyenne TT, et al. Effects of deprivation and replacement by percutaneous 17 β-oestradiol and oral progesterone on blood pressure and metabolic parameters in menopause patients with non-insulin-dependent diabetes. Arch Mal Coeur Vaiss 1991; 84: 1111–5

    PubMed  CAS  Google Scholar 

  35. Andersson B, Mårin P, Lissner L, et al. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405–11

    Article  PubMed  CAS  Google Scholar 

  36. Hazzaul WR. Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects. Am J Obstet Gynecol 1989; 161: 1847–53

    Google Scholar 

  37. Lyons TJ, Lopes-Virella MF, Baystle JW. Glycation, oxidation, and glyoxidation in the pathogenesis of atherosclerosis in diabetes. Mod Med 1993; 61Suppl. 2: 4–8

    Google Scholar 

  38. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentration and metabolism of lipoproteins. N Engl J Med 1991; 325: 1196–204

    Article  PubMed  CAS  Google Scholar 

  39. Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest 1983; 72: 743–7

    Article  PubMed  CAS  Google Scholar 

  40. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925–30

    Article  PubMed  CAS  Google Scholar 

  41. Mijatovic V, Kenemans P, Netelenbos JC, et al. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein (a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 1997; 82: 3543–7

    Article  PubMed  CAS  Google Scholar 

  42. Mattsson LÅ, Samsioe G, Schoultz B, et al. Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women. Br J Obstet Gynecol 1993; 100: 450–3

    Article  CAS  Google Scholar 

  43. Robinson JG, Folsom AR, Nabulsi AA, et al. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? Diabetes Care 1996; 19: 480–5

    Article  PubMed  CAS  Google Scholar 

  44. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34

    Article  PubMed  CAS  Google Scholar 

  45. Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88(Pt 1): 1421–30

    Article  PubMed  CAS  Google Scholar 

  46. Fontbonne A, Eschwège E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300–4

    Article  PubMed  CAS  Google Scholar 

  47. Basdevant A, DeLigneres B, Guy-Grand B. Differential lipemic and hormonal responses to oral and parenteral 17 beta-estradiol in postmenopausal women. Am J Obstet Gynecol 1983; 147: 77–81

    PubMed  CAS  Google Scholar 

  48. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998; 158: 617–21

    Article  PubMed  CAS  Google Scholar 

  49. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population: sixteenyear follow-up study. Diabetes Care 1990; 13: 631–54

    Article  Google Scholar 

  50. Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. Diabetologia 1997; 40: 711–7

    Article  PubMed  CAS  Google Scholar 

  51. Darvi G, Catalons I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769–74

    Article  Google Scholar 

  52. Carmassi F, Morale M, Pucetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643–54

    Article  PubMed  CAS  Google Scholar 

  53. Betteridge DJ. Diabetic dyslipidemia. Am J Med 1994; 96Suppl. 6A: 25–31S

    Article  Google Scholar 

  54. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in non-insulin dependent diabetes. Circulation 1994; 90: I–50–3

    Article  Google Scholar 

  55. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997; 29: 691–9

    Article  PubMed  CAS  Google Scholar 

  56. Kaplan RC, Heckbert SR, Weiss NS, et al. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care 1998 Jul; 21: 1117–21

    Article  PubMed  CAS  Google Scholar 

  57. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786–91

    Article  PubMed  CAS  Google Scholar 

  58. Fowlkes L, Sullivan JM. Estrogens, blood pressure and cardiovascular disease. Cardiol Rev 1995; 3: 106–14

    Article  Google Scholar 

  59. Stevenson JC. Assessments of therapeutic options for prevention of bone loss. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis. Copenhagen: Osteopress, 1987: 489–93

    Google Scholar 

  60. Bouillon R. Diabetic bone disease: low turnover osteoporosis related to decreased IGF-1 production. Verh K Acad Geneeskd Belg 1992; 54: 365–91

    PubMed  CAS  Google Scholar 

  61. Saneshige S. Spinal bone mineral density in the female diabetic population [in Japanese]. Nippon Roonen Igakkai Zasshi 1992; 29: 864–73

    Article  CAS  Google Scholar 

  62. Wakasugi M, Wakao R, Tawata M, et al. Bone mineral density as measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1993; 14: 29–33

    Article  PubMed  CAS  Google Scholar 

  63. Stevenson JC, Lees B, Devenport M, et al. Determinants of bone density in normal women: risk factors for future osteoporosis. BMJ 1989; 298: 924–8

    Article  PubMed  CAS  Google Scholar 

  64. Barrett-Connor E. Hormone replacement and cancer. Br Med Bull 1992; 48: 345–55

    PubMed  CAS  Google Scholar 

  65. Persson I, Adami HO, Bergkvist L. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1988; 298: 147–51

    Article  Google Scholar 

  66. La Vecchia C, Negri E, Franceschi S, et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70: 950–3

    Article  PubMed  Google Scholar 

  67. Maatela J, Aromaa A, Salmi T. The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir et Gynaecol 1994; 208 Suppl.: 20–4

    CAS  Google Scholar 

  68. Dahlgren E, Friberg L-G, Johansson S, et al. Endometrial carcinoma: ovarian dysfunction — a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991; 41: 143–50

    Article  PubMed  CAS  Google Scholar 

  69. Lapidus L, Helgesson O, Merck C, et al. Adipose tissue distribution and female carcinomas: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Int J Obes 1988; 12: 361–8

    PubMed  CAS  Google Scholar 

  70. Lundgren H, Bergström C, Blohme G, et al. Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: results from a prospective study in Gothenburg, Sweden. Int J Obes 1989; 13: 413–23

    PubMed  CAS  Google Scholar 

  71. Stanford JL, Weiss NS, Voigt LF, et al. Combined oestrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137–42

    Article  PubMed  CAS  Google Scholar 

  72. Folsom AR, Minic PJ, Sellers TA, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Publ Health 1995; 85: 1128–31

    Article  CAS  Google Scholar 

  73. Whitcroft SIJ, Stevenson JC. Hormone replacement therapy: risks and benefits. Clin Endocrinol 1992; 36: 15–20

    Article  CAS  Google Scholar 

  74. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93

    Article  PubMed  CAS  Google Scholar 

  75. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59

    Article  Google Scholar 

  76. Cummings SR, Eckert S, Krueger KA, et al. The effect of ral oxifene on risk of breast cancer in postmenopausal women: results from the MORE trial. JAMA 1999; 281: 2189–97

    Article  PubMed  CAS  Google Scholar 

  77. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic aspects. Diabetologia 1993; 36: 1119–25

    Article  PubMed  CAS  Google Scholar 

  78. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–8

    Article  PubMed  CAS  Google Scholar 

  79. Ceriello A, Quatraro A, Marchi E, et al. The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. Diabet Med 1990; 7: 343–8

    Article  PubMed  CAS  Google Scholar 

  80. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone therapy. Lancet 1996; 348: 977–80

    Article  PubMed  CAS  Google Scholar 

  81. Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3

    Article  PubMed  CAS  Google Scholar 

  82. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–8

    Article  PubMed  CAS  Google Scholar 

  83. Hahn L, Mattsson L-Å, Andersson B, et al. The effects of estrogen replacement therapy on haemostasis variables in postmenopausal women with noninsulin-dependent diabetes mellitus. Blood Coag Fibrinol 1999; 10: 81–6

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Sahlgrenska University Hospital/Sahlgrenska, Göteborg University, Sweden

    Björn Andersson

Authors
  1. Björn Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn Andersson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andersson, B. Hormone Replacement Therapy in Postmenopausal Women With Diabetes Mellitus. Drugs & Aging 17, 399–410 (2000). https://doi.org/10.2165/00002512-200017050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200017050-00006

Keywords

Search

Navigation